Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Avacta to Present at Leerink Healthcare Conference

10th Mar 2025 07:00

RNS Number : 8864Z
Avacta Group PLC
10 March 2025
 

 

 

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference

 

 

LONDON and PHILADELPHIA - March 10, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami.

 

A live webcast of the presentation will be available in the investors section of the Company's website at https://avacta.com/investors. The webcast will be archived for at least 30 days following the presentation.

 

-Ends-

For further information from Avacta, please contact:

 

Avacta Group plc

Michael Vinegrad, Group Communications

Director

avacta.com

Peel Hunt (Nomad and Broker)

James Steel / Chris Golden / Patrick Birkholm

 

 

 

www.peelhunt.com

 

Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers

 

www.panmureliberum.com

ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Max Bennett

 

[email protected]

 

 

Investor Contact

Renee Leck

THRUST Strategic Communications

 

 

 

[email protected]

 

Media Contact

Carly Scaduto

Carly Scaduto Consulting

 

[email protected] 

 

 

About Avacta avacta.com  

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBLGDXUSGDGUR

Related Shares:

Avacta Group
FTSE 100 Latest
Value8,595.71
Change53.15